AVEO:NSD-AVEO Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 5.52

Change

+0.06 (+1.10)%

Market Cap

USD 0.18B

Volume

0.19M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


AVEO Pharmaceuticals Inc (AVEO) Stock Analysis:
Based on the AVEO Pharmaceuticals Inc stock forecasts from 2 analysts, the average analyst target price for AVEO Pharmaceuticals Inc is USD 0.00 over the next 12 months. AVEO Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of AVEO Pharmaceuticals Inc is Bearish, which is based on 2 positive signals and 9 negative signals. At the last closing, AVEO Pharmaceuticals Inc’s stock price was USD 5.52. AVEO Pharmaceuticals Inc’s stock price has changed by -0.77 % over the past week, -1.82 % over the past month and +3.56 % over the last year.

About

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-12-07 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

+17.02 (+6.41%)

USD122.24B 18.38 14.64
BNTX BioNTech SE

+22.86 (+8.17%)

USD83.44B 8.87 7.65
REGN Regeneron Pharmaceuticals Inc

+10.09 (+1.61%)

USD68.31B 10.00 7.78
VRTX Vertex Pharmaceuticals Incorpo..

+0.16 (+0.08%)

USD51.82B 24.59 15.60
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

+18.04 (+6.03%)

USD33.26B N/A N/A
SGEN Seagen Inc

+0.43 (+0.29%)

USD27.56B 55.02 44.86
GMAB Genmab A/S

+1.82 (+4.93%)

USD24.43B 55.83 6.05
ALNY Alnylam Pharmaceuticals Inc

+3.28 (+1.85%)

USD20.49B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing AVEO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.33% 72% C- 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.33% 72% C- 37% F
Trailing 12 Months  
Capital Gain 3.56% 73% C 47% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.56% 73% C 45% F
Trailing 5 Years  
Capital Gain 801.96% 94% A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 801.96% 94% A 96% A
Average Annual (5 Year Horizon)  
Capital Gain 210.12% 93% A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 210.12% 93% A 96% A
Risk Return Profile  
Volatility (Standard Deviation) 355.26% 7% F 5% F
Risk Adjusted Return 59.15% 87% B+ 76% C
Market Capitalization 0.18B 41% F 32% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 84.80 13% F 13% F
Price/Book Ratio 3.58 43% F 35% F
Price / Cash Flow Ratio -4.83 44% F 66% D
EV/EBITDA 48.85 10% F 16% F
Management Effectiveness  
Return on Equity -125.94% 20% F 16% F
Return on Invested Capital -97.59% 20% F 8% F
Return on Assets -38.50% 23% F 8% F
Debt to Equity Ratio 36.03% 30% F 46% F
Technical Ratios  
Short Ratio 7.00 32% F 17% F
Short Percent 5.18% 40% F 31% F
Beta 1.12 57% F 48% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector